From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function

被引:137
作者
Douglas, SA
Dhanak, D
Johns, DG
机构
[1] GlaxoSmithKline, Cardiovasc & Urogenital Ctr Excellence Drug Disco, Dept Vasc Biol, King Of Prussia, PA 19406 USA
[2] GlaxoSmithKline, Microbial Musculoskeletal & Proliferat Dis Ctr Ex, Dept Oncol Chem, Collegeville, PA 19426 USA
关键词
D O I
10.1016/j.tips.2003.12.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The identification of a human homolog of urotensin-II (U-II) and a novel, specific G-protein-coupled receptor by Ames et al. in 1999 changed the perception that the U-II isopeptide family was an esoteric collection of 'somatostatin-like neuropeptides' present only in the nervous systems of an eclectic array of aquatic invertebrates, fish and amphibians. In this article, we review recent developments in the pharmacology of human U-II, focusing on the actions of this peptide in the mammalian cardiorenal system. The putative role of U-II in the etiology of hypertension, heart failure, renal dysfunction and diabetes is discussed, as are novel U-II receptor antagonists.
引用
收藏
页码:76 / 85
页数:10
相关论文
共 99 条
[1]   Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats [J].
Abdelrahman, AM ;
Pang, CCY .
LIFE SCIENCES, 2002, 71 (07) :819-825
[2]   No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans [J].
Affolter, JT ;
Newby, DE ;
Wilkinson, IB ;
Winter, MJ ;
Balment, RJ ;
Webb, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (06) :617-621
[3]  
AISSAOUI H, 2002, Patent No. 0276979
[4]   Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J].
Ames, RS ;
Sarau, HM ;
Chambers, JK ;
Willette, RN ;
Alyar, NV ;
Romanic, AM ;
Louden, CS ;
Foley, JJ ;
Sauermelch, CF ;
Coatney, RW ;
Ao, ZH ;
Disa, J ;
Holmes, SD ;
Stadel, JM ;
Martin, JD ;
Liu, WS ;
Glover, GI ;
Wilson, S ;
McNulty, DE ;
Ellis, CE ;
Elshourbagy, NA ;
Shabon, U ;
Trill, JJ ;
Hay, DWP ;
Ohlstein, EH ;
Bergsma, DJ ;
Douglas, SA .
NATURE, 1999, 401 (6750) :282-286
[5]   Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist [J].
Behm, DJ ;
Herold, CL ;
Ohlstein, EH ;
Knight, SD ;
Dhanak, D ;
Douglas, SA .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 137 (04) :449-458
[6]   Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice [J].
Behm, DJ ;
Harrison, SM ;
Ao, ZH ;
Maniscalco, K ;
Pickering, SJ ;
Grau, EV ;
Woods, TN ;
Coatney, RW ;
Doe, CPA ;
Willette, RN ;
Johns, DG ;
Douglas, SA .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 139 (02) :464-472
[7]  
BENNETT T, 2002, BRIT J PHARMACOL, V135, P200
[8]  
Bern H.A., 1985, Recent Progress in Hormone Research, V41, P533
[9]   Urotensin II evokes potent vasoconstriction in humans in vivo [J].
Böhm, F ;
Pernow, J .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (01) :25-27
[10]   Plasma concentrations of arginine vasotocin and urotensin II are reduced following transfer of the euryhaline flounder (Platichthys flesus) from seawater to fresh water [J].
Bond, H ;
Winter, MJ ;
Warne, JM ;
McCrohan, CR ;
Balment, RJ .
GENERAL AND COMPARATIVE ENDOCRINOLOGY, 2002, 125 (01) :113-120